Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.

摘要: The widespread adoption of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the first-line treatment patients with advanced EGFR-mutated non-small cell lung cancer has resulted in acquired inhibitor resistance becoming a ubiquitous clinical problem. identification specific mechanisms allowed better understanding biology and natural history resistant disease, but is only now starting to impact decisions. Strategies managing are complex must be adapted individual characteristics each patient's cancer. Although combination chemotherapy presumed standard care most patients, prospective trial data lacking, highlighting importance offering participation trials this setting. Emerging from third-generation mutant-specific EGFR suggests particular promise class agents.